Navigation Links
Center releases new public survey on stem cells

Stem cells are unique among human cells in that they possess the uncanny ability to develop into virtually any other cell of the body, offering a hypothetical tool kit for repairing diseased hearts, mending broken spinal cords, or correcting genetic diseases, among other hoped-for benefits. Stem cells derived from very early embryos show the most promise in research to date, but the embryo is destroyed in the process of acquiring the cells themselves. This outcome is not acceptable to individuals and institutions that believe human life at all stages of development deserves protection and should not be destroyed.

Much current debate focuses on whether other sources of stem cells - blood from the umbilical cord removed at birth, for example - might be as useful without the need to destroy embryos, but the scientific consensus so far is that embryos remain the best research choice. Typically, the embryos used are those remaining at the conclusion of fertility treatments that would otherwise be discarded or kept in frozen storage; a ban on the use of Federal funds to create new stem cells using these embryos currently is in effect, and various pieces of legislation pending in Congress would either extend this ban or relax it.

A survey of 2,212 Americans conducted September 9-19, reveals a public opinion landscape that bears little resemblance to the polarized, deep moral divide expressed on the floor of the Congress and in the op-ed pages of American newspapers.

The survey found wide support for embryonic stem cell (ESC) research that cut across political, religious and socio-economic lines, with two-thirds of respondents either approving or strongly approving of human embryonic stem cell research. Even Fundamentalist and Evangelical Christians - long considered to be the most hard-line opponents of embryonic stem cell studies -- split evenly on approval for embryonic stem cell research.

Respondents were given a choice of four ESC re search policy options: banning all embryonic stem cell research, retaining the current Bush administration policy, relaxing restrictions along the lines of some Congressional proposals that would allow federal funding of research using embryonic stem cell lines created using private funds, and unqualified Federal support for embryonic stem cell creation and research.

Twenty-two percent of respondents expressed support for the current Bush administration policy; fewer still (16 percent), would ban embryonic stem cell research altogether. A majority favored relaxing embryonic stem cell restrictions, including 40 percent who would support federal funding for both the creation of new embryonic stem cell lines and further research using them.

The survey also explored how potential future changes in the scientific landscape might affect public opinion. Respondents were asked to imagine two scenarios - the development of a technique to isolate ESCs without destroying embryos, or a major advance in treating disease based on embryonic stem cell technologies. About 25 percent of respondents who initially favored the current policy or a complete ban of ESC research indicated that if the treatment scenario were to materialize, they would support a public policy for ESC research that is more supportive than their initial policy position. Similarly, if the alternative scenario were to materialize, 16 percent of respondents who currently endorse a public policy towards ESC research that is more permissive than the current public policy would then support ESC research only if embryos were not destroyed.

The survey looked beyond overall attitudes toward ESC research to explore the competing values that underlie them. Survey respondents were asked a series of questions designed to ascertain the value placed on progress in ESC research and protecting early human embryos. The survey revealed a subtle topography of the public's attitudes with only a small fraction (6 percent at each pole) of the public occupying the extreme positions that so frequently characterize the public and policy debate. Fully half expressed agreement both with statements that placed high priority on protecting human embryos and with statements that placed high priority on searching for medical cures through ESC research. When asked in a single item which was more important, 60 percent selected ESC research and 37 percent selected not destroying embryos.

While the moral status of human embryos has been the centerpiece of the political debate about ESC research, often articulated as an all-or-nothing proposition that is fully predictive of all of an individual's other views on embryonic stem cell research, the public's views about the moral status of embryos and the relationship of those views to ESC research policy preferences has not been fully explored. The survey showed that nearly the same number of Americans believe that an embryo in a Petri dish has no or low moral status (30 percent) or maximum moral status (28 percent). The remainder (42 percent) accord embryos some intermediate moral status.

A third of those who believe an embryo in a Petri dish has maximum moral status nonetheless approve of ESC research. Similarly, a third support ESC research policies more permissive than the current policy and which involve funding for research using new ESCs.

In a parallel fashion, 17 percent of those who accord an embryo in a Petri dish no or low moral status nevertheless disapprove of ESC research and support the current ESC policy or an all-out ban (22 percent). Thus, even for a sizeable number of respondents who fall at the polar ends of the moral status continuum, the commonly held expectation that they will support the corresponding policy extreme does not hold true.


'"/>

Source:Genetics & Public Policy Center, Johns Hopkins University


Related biology news :

1. Fox Chase Cancer Center scientists identify immune-system mutation
2. Emory Eye Center Implants Its First Retinal Chips In Patients With Retinitis Pigmentosa
3. Massey Cancer Center researcher helps to identify a piece of the cancer puzzle
4. $6.5 Million Grant for Microarray Center at Yale School of Medicine
5. Woods Hole Research Center plans controlled burn in Amazon rainforest
6. VCU Massey Cancer Center study shows enzyme linked to spread of breast cancer cells
7. World Trade Center identifications pushed forensic DNA technology
8. VCU Massey Cancer Center researchers identify a new class of anti-cancer drugs based on platinum
9. Mayo Clinic Cancer Center: Harnessing the measles virus to attack cancer
10. MSI releases moleculizer - a new approach to simulation of intracellular biochemical networks
11. Agilent Technologies releases automated literature search tool for biology researchers
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/20/2016)... Securus Technologies, a leading provider of ... safety, investigation, corrections and monitoring announced that after ... secured the final acceptance by all three (3) ... Systems (MAS) installed. Furthermore, Securus will have contracts ... by October, 2016. MAS distinguishes between legitimate wireless ...
(Date:6/7/2016)... , June 7, 2016  Syngrafii Inc. ... a business relationship that includes integrating Syngrafii,s patented ... branch project. This collaboration will result in greater ... the credit union, while maintaining existing document workflow ... http://photos.prnewswire.com/prnh/20160606/375871LOGO ...
(Date:6/1/2016)... 2016 Favorable Government Initiatives Coupled ... Criminal Identification to Boost Global Biometrics System Market Through ... Research report, " Global Biometrics Market By Type, ... Opportunities, 2011 - 2021", the global biometrics market is ... account of growing security concerns across various end use ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... 23, 2016   EpiBiome , a precision microbiome ... in debt financing from Silicon Valley Bank (SVB). The ... to advance its drug development efforts, as well as ... "SVB has been an incredible strategic partner to ... traditional bank would provide," said Dr. Aeron Tynes ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... at the Pennsylvania Convention Center and will showcase its product’s latest features from ... also be presenting a scientific poster on Disrupting Clinical Trials in The Cloud ...
(Date:6/23/2016)... India , June 23, 2016 ... media market research report to its pharmaceuticals section ... profiles, product details and much more. ... spread across 151 pages, profiling 15 companies and ... available at http://www.reportsnreports.com/reports/601420-global-cell-culture-media-industry-2016-market-research-report.html . ...
Breaking Biology Technology: